Fresenius Kabi Recalls Tyenne (tocilizumab-aazg) Injection Due to Glass Particles

Fresenius Kabi has initiated a recall of one batch of its biosimilar Tyenne (tocilizumab-aazg) injection in 20 ml vials in the U.S. after a company investigation identified the presence of glass particles in the product. Injecting medication contaminated with glass particulates could lead to irritation, pain, swelling at the infusion site, potential inflammation of veins, and in more serious cases, blockage and clotting of blood vessels.